173 related articles for article (PubMed ID: 11842430)
21. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB.
Lebowitz PF; Casey PJ; Prendergast GC; Thissen JA
J Biol Chem; 1997 Jun; 272(25):15591-4. PubMed ID: 9188444
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
23. Cenp-F (mitosin) is more than a mitotic marker.
Varis A; Salmela AL; Kallio MJ
Chromosoma; 2006 Aug; 115(4):288-95. PubMed ID: 16565862
[TBL] [Abstract][Full Text] [Related]
24. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.
Sebti SM
Cancer Cell; 2005 Apr; 7(4):297-300. PubMed ID: 15837619
[TBL] [Abstract][Full Text] [Related]
25. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298.
Allal C; Pradines A; Hamilton AD; Sebti SM; Favre G
Cell Cycle; 2002; 1(6):430-7. PubMed ID: 12548020
[TBL] [Abstract][Full Text] [Related]
26. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
Thomas X; Elhamri M
Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
[TBL] [Abstract][Full Text] [Related]
27. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
28. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
29. Geranylgeranylated proteins are involved in the regulation of myeloma cell growth.
van de Donk NW; Lokhorst HM; Nijhuis EH; Kamphuis MM; Bloem AC
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):429-39. PubMed ID: 15701825
[TBL] [Abstract][Full Text] [Related]
30. An overview of farnesyltransferase inhibitors and their role in lung cancer therapy.
Adjei AA
Lung Cancer; 2003 Aug; 41 Suppl 1():S55-62. PubMed ID: 12867063
[TBL] [Abstract][Full Text] [Related]
31. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
32. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation.
Clark GJ; Kinch MS; Rogers-Graham K; Sebti SM; Hamilton AD; Der CJ
J Biol Chem; 1997 Apr; 272(16):10608-15. PubMed ID: 9099708
[TBL] [Abstract][Full Text] [Related]
33. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
[TBL] [Abstract][Full Text] [Related]
34. Blocked pathways: FTIs shut down oncogene signals.
Sebti SM
Oncologist; 2003; 8 Suppl 3():30-8. PubMed ID: 14671226
[TBL] [Abstract][Full Text] [Related]
35. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells.
Miquel K; Pradines A; Sun J; Qian Y; Hamilton AD; Sebti SM; Favre G
Cancer Res; 1997 May; 57(10):1846-50. PubMed ID: 9157972
[TBL] [Abstract][Full Text] [Related]
36. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
Du W; Prendergast GC
Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
[TBL] [Abstract][Full Text] [Related]
37. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
Crul M; de Klerk GJ; Beijnen JH; Schellens JH
Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
[TBL] [Abstract][Full Text] [Related]
38. Farnesyl transferase inhibitors in the treatment of breast cancer.
Kelland LR
Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
[TBL] [Abstract][Full Text] [Related]
39. Evolving therapies: farnesyltransferase inhibitors.
Purcell WT; Donehower RC
Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
[TBL] [Abstract][Full Text] [Related]
40. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.
Moasser MM; Sepp-Lorenzino L; Kohl NE; Oliff A; Balog A; Su DS; Danishefsky SJ; Rosen N
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1369-74. PubMed ID: 9465021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
